Bard PowerPort Lawsuit 2026: MDL 3081 Claims & Status

The Bard PowerPort, an implanted port catheter used for repeated vascular access such as chemotherapy, is the subject of product liability claims alleging that the catheter can fracture or move after it is implanted. The federal cases are coordinated in a multidistrict litigation in Arizona. This page explains the claims, the FDA record, and the current status neutrally, including the fact that the first test trial went against the plaintiff. It is general information and attorney advertising, not legal advice, and not a statement that anyone has a claim.

This page is part of our Mass Tort & Product Liability overview.

What the PowerPort litigation is about

A port catheter, sometimes called a chemo port, is a small device implanted under the skin and connected to a catheter that threads into a large vein, allowing clinicians to deliver chemotherapy, fluids, nutrition, or contrast and to draw blood without repeated needle sticks. The lawsuits focus on the Bard PowerPort family of devices and allege that the catheter component can fracture, crack, degrade, or move out of position after implantation. Plaintiffs allege specifically that the catheter is made with a concentration of barium sulfate, a material that makes the device visible on imaging, that is high enough to weaken the polyurethane and make it prone to failure. The legal claims include design defect, manufacturing defect, and failure to warn. These are allegations that plaintiffs must prove, and the manufacturers deny that the devices are defective.

Note: These are allegations being tested in court. Port catheters are widely used and most function as intended, and a complication does not by itself establish that a device was defective or that any manufacturer is liable.

The alleged injuries

The injuries alleged in the litigation generally stem from the catheter fracturing or migrating. Plaintiffs allege that a fractured catheter can send fragments traveling through the bloodstream, and that fracture or migration can lead to blood clots, infection or bloodstream infection, perforation of a vein or the heart, irregular heart rhythm when a fragment reaches the heart, and the need for a procedure to locate and remove the device or a fragment. The severity differs greatly from person to person, and whether any of these outcomes was caused by a defect in the device, rather than by other medical factors, is contested. Describing the alleged injuries is not a statement that the device caused any individual person's harm.

What the FDA record shows

The Bard PowerPort devices reached the U.S. market through the FDA's 510(k) clearance pathway, which clears a device based on similarity to an existing product and generally does not require new clinical trials, rather than the more rigorous premarket approval used for the highest-risk devices. The FDA's adverse-event database contains thousands of reports referencing PowerPort devices, though such reports are voluntary, unverified, and do not establish that a device caused the reported harm. It is important to be precise about recalls: the FDA has recorded a number of PowerPort-related recalls, but they were classified as the less serious type and involved administrative issues such as labeling discrepancies and flushing instructions. As of mid-2026, the FDA had not issued a recall over the catheter-fracture or barium-sulfate problem that is at the center of the lawsuits, a point the defense raises and that any reader should weigh.

Note: An adverse-event report or an administrative recall does not resolve the legal question. The litigation is about whether the catheter has a fracture-related design or manufacturing defect, which the manufacturers dispute and which no FDA recall has addressed.

The status of the litigation (as of June 2026)

The federal cases are consolidated in MDL No. 3081 in the District of Arizona before Senior Judge David G. Campbell, who previously oversaw the Bard IVC filter litigation, and the Judicial Panel on Multidistrict Litigation created the MDL in August 2023. As of the panel's June 2026 statistics, more than 3,300 cases were pending. The first bellwether trial reached a verdict in 2026 in the defendants' favor on the failure-to-warn and fraud claims, and according to reporting the jury did not reach a verdict on the separate design-defect claim, with the plaintiff seeking further proceedings afterward. Additional test trials were reported to be scheduled into 2026 and beyond. There is no settlement as of June 2026, and reported settlement values circulating online are not based on any actual settlement, which does not exist.

Who may be involved

The people generally involved in this litigation are those who received a Bard PowerPort or similar Bard implanted port and allege an injury connected to the catheter fracturing, migrating, or a related complication. Whether any particular person may have a claim depends on the specific facts, including which device was implanted and when, the nature and documentation of the complication, the medical records, and the law of the relevant state, and the cases must also account for the first test trial having favored the defense. Having had a port implanted does not by itself establish a claim, and nothing here suggests that every patient has one or that any outcome is assured.

Deadlines and why they matter

Claims like these are subject to statutes of limitations, the legal deadlines to file suit, which vary by state and by the type of claim, commonly in the range of two to three years but ranging more widely. Many states measure the deadline from when a person knew or reasonably should have known that an injury was connected to the device, a concept called the discovery rule, rather than from the implant date. Some states also have statutes of repose, and a coordinated litigation can have its own case-management deadlines. There is no single national deadline, and this page does not state any individual's deadline. A licensed attorney in the relevant state can determine what applies, and missing a deadline can permanently bar a claim.

How to evaluate your options

If you are trying to understand your legal options, the appropriate step is to speak with a licensed attorney who handles this type of case. An attorney can assess the facts, explain the law in your state, and advise whether you may have a claim, which this page cannot do, and can take into account that the first test trial favored the defense and that no FDA fracture recall exists. It helps to gather any records you have, such as the implant records identifying the specific device, your medical records documenting the complication and any removal procedure, and the relevant dates. Most mass tort and personal injury attorneys offer a free, confidential consultation and work on a contingency basis, meaning a fee is generally owed only if there is a recovery. A consultation creates no obligation.